Key Takeaways
What CPAP Therapy for OSA Is and How It Works
CPAP therapy for OSA uses a bedside machine that pushes a constant stream of air through a mask over the nose, mouth or both, holding the upper airway open during sleep[7]. The National Heart, Lung, and Blood Institute describes positive airway pressure as the most common treatment for sleep apnea[7].
Obstructive sleep apnea (OSA) is defined by more than 5 episodes per hour of partial or complete upper-airway blockage during sleep despite efforts to breathe[1]. Medicare lists mood disorders, impaired cognition and insomnia among the symptoms that can qualify a person with milder OSA for CPAP[8]. Those symptoms overlap with mental illness, whose U.S. prevalence is tracked on its own page.
CPAP, APAP and BPAP
CPAP is one of three positive airway pressure (PAP) device types[7]. An auto-adjusting machine (APAP) changes the pressure through the night, and a bilevel machine (BPAP or BiPAP) delivers one pressure when breathing in and a lower one when breathing out[7].
The American Academy of Sleep Medicine (AASM) recommends either CPAP or APAP for ongoing treatment and suggests both over BPAP for routine OSA[2]. Treatment can start with APAP at home or with a pressure titration in a sleep laboratory for adults without significant comorbidities[2].
Apnea-hypopnea index (AHI)
The number of apneas (total airway blockage of more than 90% lasting over 10 seconds) and hypopneas (partial blockage of more than 30% with a drop in blood oxygen or an arousal) per hour of sleep[1]. The USPSTF evidence review grades severity as mild at 5 to 15 events per hour, moderate at 16 to 30 and severe above 30[1].
Related Terms
Source: USPSTF evidence review, JAMA, 2022
Who Gets CPAP? What the AASM Guideline Recommends
The AASM's 2019 clinical practice guideline sets out who should receive PAP therapy and how it should be started and supported[2]. Each recommendation is graded strong or conditional[2].
The only strong recommendation on who should be treated covers adults with OSA and excessive daytime sleepiness[2]. For adults with impaired sleep-related quality of life or with high blood pressure, the guideline makes a weaker, conditional suggestion[2].
The guideline also strongly recommends educational interventions when therapy starts. Behavioral support, troubleshooting and remote telemonitoring of device data during the first weeks are conditional suggestions[2].
AASM Recommendations for PAP Therapy in Adults With OSA, 2019
| Recommendation | Strength |
|---|---|
| PAP vs. no therapy for OSA with excessive sleepiness | Strong |
| PAP vs. no therapy for impaired sleep-related quality of life | Conditional |
| PAP vs. no therapy for OSA with comorbid hypertension | Conditional |
| Start with home APAP or in-lab titration (no significant comorbidities) | Strong |
| CPAP or APAP for ongoing treatment | Strong |
| CPAP or APAP over BPAP for routine treatment | Conditional |
| Educational interventions at the start of therapy | Strong |
| Behavioral, troubleshooting and telemonitoring support | Conditional |
Recommendation statements from the American Academy of Sleep Medicine clinical practice guideline on positive airway pressure for adult obstructive sleep apnea, 2019[2].
1The first six rows are the guideline's numbered recommendations; the last two summarize its statements on support during the first weeks of therapy.
Sources
- •American Academy of Sleep Medicine, 2019
How Well CPAP Works: Sleepiness, Quality of Life and Blood Pressure
A 2022 evidence review for the U.S. Preventive Services Task Force (USPSTF) pooled the randomized trials of positive airway pressure[1]. Across 47 trials with 7,024 adults, positive airway pressure lowered Epworth Sleepiness Scale scores by 2.33 points more than inactive control[1]. The review put the smallest change patients notice at 2 to 3 points, so the average effect sits at the low end of that range[1].
Sleep-related quality of life improved modestly, with a standardized mean difference of 0.30 across 17 trials and 3,083 participants[1]. General health scores on the SF-36 also rose, but the mental component gain of 2.20 points fell below the 4 to 7 point threshold the review lists as clinically important[1].
Blood pressure fell in 3 systematic reviews of positive airway pressure, though the drop was small, about 2 to 3 mm Hg[1]. The effect on breathing events is larger: in the SAVE trial, the mean AHI among CPAP users fell from 29.0 events per hour at baseline to 3.7 during follow-up[3].
Pooled Effects of Positive Airway Pressure vs. Inactive Control
| Outcome | Trials | Participants | Pooled effect (95% CI) | Smallest important change |
|---|---|---|---|---|
| Epworth Sleepiness Scale | 47 | 7,024 | -2.33 (-2.75 to -1.90) | -2 to -3 |
| Sleep-related quality of life (all measures) | 17 | 3,083 | SMD 0.30 (0.19 to 0.42) | Not applicable |
| SF-36 mental component | 15 | 2,345 | 2.20 (0.95 to 3.44) | 4 to 7 |
| SF-36 physical component | 13 | 2,031 | 1.53 (0.29 to 2.77) | 4 to 7 |
Mean differences from randomized trials of positive airway pressure in adults with OSA, pooled in the 2022 USPSTF evidence review[1].
1SMD = standardized mean difference. A negative Epworth change means less sleepiness; positive quality-of-life changes mean improvement.
Sources
- •Feltner et al., JAMA, 2022
Average drop in Epworth Sleepiness Scale score with positive airway pressure vs. inactive control, 47 trials
The review set the smallest change patients notice at 2 to 3 points, so CPAP's average benefit on sleepiness is real but modest.
"pooled mean difference, -2.33 [95% CI, -2.75 to -1.90]; 47 trials; n = 7024"
Does CPAP Prevent Heart Attacks and Strokes? The SAVE Trial
OSA is associated with an increased risk of cardiovascular events, so the SAVE investigators tested whether CPAP prevents them[3]. The SAVE trial randomly assigned 2,717 adults aged 45 to 75 with moderate-to-severe OSA and coronary or cerebrovascular disease to CPAP plus usual care or usual care alone[3].
After a mean of 3.7 years, a cardiovascular death, heart attack, stroke or related hospitalization had occurred in 17.0% of the CPAP group and 15.4% of the usual-care group, a difference that was not statistically significant[3]. CPAP did reduce snoring and daytime sleepiness and improved quality of life and mood[3].
Use also fell over time. Average CPAP use was 4.4 hours per night in the first month, 3.5 hours by 12 months and 3.3 hours across follow-up[3]. Across the wider trial evidence, the USPSTF review likewise found that no included trial found a significant benefit of treatment on mortality, cardiovascular events or motor vehicle crashes[1].
CPAP and Depression: What the Trials Found
Mood was a secondary outcome in SAVE, and the results bear on depression. In SAVE, the share of patients with clinically relevant depression scores was 25% to 30% lower in the CPAP group than in the usual-care group at the end of follow-up[3].
A 2019 secondary analysis of 2,410 SAVE patients found CPAP was associated with lower odds of depression caseness, defined as a score of 8 or more on the Hospital Anxiety and Depression Scale (adjusted odds ratio 0.80)[4]. The effect was larger in people who already had depressive symptoms[4].
The same paper pooled 20 randomized trials with 4,255 participants and found a small overall reduction in depressive symptoms, a standardized mean difference of -0.18[4]. Neither the SAVE analysis nor the pooled trials showed an effect on anxiety caseness[4].
These results come mostly from people whose primary diagnosis was OSA, many with heart or vascular disease, so they describe CPAP's effect on mood symptoms in that group. They do not show that CPAP treats major depression in people without OSA.
How Many Hours a Night Is Enough? Adherence, Side Effects and the Philips Recall
No single nightly target applies in every study, but Medicare uses a fixed benchmark: at least 4 hours per night on 70% of nights during a consecutive 30-day period within the first 3 months[6].
A review of 82 studies published over 20 years put the overall non-adherence rate at 34.1%, calculated against a 7-hour night of sleep, and found no improvement across that period[5].
Side effects
The NHLBI lists congestion, dry eyes or mouth, nosebleeds and a runny nose as possible side effects, and advises contacting a clinician about stomach discomfort or bloating[7]. The AASM guideline suggests troubleshooting, behavioral and telemonitoring support during the initial period of PAP therapy[2].
The Philips recall
In June 2021, Philips Respironics recalled certain CPAP machines, BiPAP machines and ventilators, a recall affecting 15 million devices worldwide[9]. The sound-dampening polyester-based polyurethane foam inside them could break down and be inhaled or swallowed, and the FDA classed it as a Class I recall, its most serious category[9]. A federal court entered a consent decree against the company on April 9, 2024[9].
Does Medicare Cover CPAP Therapy?
Medicare's national coverage rule allows an initial 12-week CPAP trial for adults with an AHI of 15 or more events per hour[8]. Adults with an AHI of 5 to 14 also qualify if they have documented excessive daytime sleepiness, impaired cognition, mood disorders or insomnia, or documented hypertension, ischemic heart disease or a history of stroke[8].
Coverage after the first 3 months requires a clinical re-evaluation between day 31 and day 91 of therapy[6]. The clinician must document that symptoms improved and review objective device data showing the adherence benchmark was met[6].
For adults 65 and older on Medicare, these rules set the terms of CPAP coverage. Because mood disorders and insomnia are named qualifying symptoms, a documented mood disorder or insomnia can affect eligibility when the AHI is 5 to 14[8].
Alternatives to CPAP for OSA
Oral appliances that hold the lower jaw forward are one non-surgical option[7]. In the USPSTF review, mandibular advancement devices lowered Epworth scores by 1.67 points across 10 trials with 1,540 participants, a smaller average change than PAP's 2.33 points[1]. The NHLBI notes they may be prescribed when a person does not want to use or cannot tolerate CPAP[7].
Hypoglossal nerve stimulation uses an implanted device to activate the nerve that moves the tongue[7]. In the STAR study of 126 people who had difficulty accepting or adhering to CPAP, the median AHI fell 68%, from 29.3 to 9.0 events per hour at 12 months[10]. STAR had no control group during that phase, which limits how far the result can be generalized[10].
On December 20, 2024, the FDA approved tirzepatide (Zepbound) as the first medication for moderate to severe OSA in adults with obesity, based on two 52-week trials with 469 adults[11]. One trial enrolled people already using PAP, and the other enrolled people unable or unwilling to use it[11].
Other options include weight-loss changes, side sleeping, tonsil removal, jaw advancement surgery and bariatric surgery[7]. Sleep medications are a separate question; the evidence on them is covered in sleeping pills.
Frequently Asked Questions
Sources & References
- Feltner C, Wallace IF, Aymes S, et al. Screening for Obstructive Sleep Apnea in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. Published 2022. Accessed October 2026. https://jamanetwork.com/journals/jama/fullarticle/2798400 [Link]
- Patil SP, Ayappa IA, Caples SM, Kimoff RJ, Patel SR, Harrod CG. Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline. Journal of Clinical Sleep Medicine. Published 2019. Accessed October 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC6374094/ [Link]
- McEvoy RD, Antic NA, Heeley E, et al. CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea. New England Journal of Medicine. Published 2016. Accessed October 2026. https://www.nejm.org/doi/full/10.1056/NEJMoa1606599 [Link]
- Zheng D, Xu Y, You S, et al. Effects of continuous positive airway pressure on depression and anxiety symptoms in patients with obstructive sleep apnoea: results from the sleep apnoea cardiovascular Endpoint randomised trial and meta-analysis. eClinicalMedicine (The Lancet). Published 2019. Accessed October 2026. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(19)30090-2/fulltext [Link]
- Rotenberg BW, Murariu D, Pang KP. Trends in CPAP adherence over twenty years of data collection: a flattened curve. Journal of Otolaryngology - Head & Neck Surgery. Published 2016. Accessed October 2026. https://journals.sagepub.com/doi/10.1186/s40463-016-0156-0 [Link]
- Centers for Medicare & Medicaid Services. Local Coverage Determination: Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea (L33718). Published 2024. Accessed October 2026. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33718 [Link]
- National Heart, Lung, and Blood Institute. Sleep Apnea Treatment. Published 2025. Accessed October 2026. https://www.nhlbi.nih.gov/health/sleep-apnea/treatment [Link]
- Centers for Medicare & Medicaid Services. National Coverage Determination: Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea (OSA) (240.4). Published 2008. Accessed October 2026. https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=226 [Link]
- U.S. Food and Drug Administration. FDA Activities Related to Recalled Philips Ventilators, BiPAP Machines, and CPAP Machines. Published 2024. Accessed October 2026. https://www.fda.gov/medical-devices/recalled-philips-ventilators-bipap-machines-and-cpap-machines/fda-activities-related-recalled-philips-ventilators-bipap-machines-and-cpap-machines [Link]
- Strollo PJ Jr, Soose RJ, Maurer JT, et al. Upper-Airway Stimulation for Obstructive Sleep Apnea. New England Journal of Medicine. Published 2014. Accessed October 2026. https://www.nejm.org/doi/full/10.1056/NEJMoa1308659 [Link]
- U.S. Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea. Published 2024. Accessed October 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea [Link]